Short-term effects of angiotensin receptor blockers on blood pressure control, and plasma inflammatory and fibrinolytic parameters in patients taking angiotensin-converting enzyme inhibitors

Creative Commons License

Agirbasli M. A. , Cincin A., Baykan O. A.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.9, no.1, pp.22-26, 2008 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 1
  • Publication Date: 2008
  • Doi Number: 10.3317/jraas.2008.004
  • Page Numbers: pp.22-26
  • Keywords: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, high sensitive C-reactive protein, hypertension, plasma plasminogen activator inhibitor, tissue plasminogen activator, PLASMINOGEN-ACTIVATOR INHIBITOR-1, CORONARY-ARTERY-DISEASE, MYOCARDIAL-INFARCTION, CARDIOVASCULAR EVENTS, RANDOMIZED-TRIAL, HEART-FAILURE, HYPERTENSIVE PATIENTS, ENDOTHELIAL-CELLS, DOUBLE-BLIND, RISK


Introduction. Angiotensin-converting enzyme (ACE) inhibitors reduce cardiovascular events in patients with established vascular disease and heart failure (HF). ACE-inhibitors have important effects on fibrinolytic balance, which may be the underlying mechanism for a reduction in cardiovascular events. Although angiotensin receptor blockers (ARBs) offer greater tolerability than ACE-inhibitors, the major ARB trials have demonstrated a lack of reduction in myocardial infarction (MI) occurrence and mortality in contrast to ACE-inhibitors. In this study, we investigated the combined effects of ARBs and ACE-inhibitors on fibrinolytic and inflammatory parameters in patients with uncontrolled hypertension.